Cambrex Co. (CBM) Forecasted to Earn FY2017 Earnings of $2.96 Per Share

Cambrex Co. (NYSE:CBM) – Stock analysts at William Blair issued their FY2017 earnings per share (EPS) estimates for Cambrex in a research note issued to investors on Tuesday. William Blair analyst J. Kreger anticipates that the biotechnology company will post earnings of $2.96 per share for the year. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Cambrex’s Q4 2017 earnings at $1.09 EPS, FY2018 earnings at $2.95 EPS, FY2019 earnings at $3.13 EPS, FY2020 earnings at $3.32 EPS and FY2021 earnings at $3.61 EPS.

CBM has been the topic of a number of other reports. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday. Craig Hallum reissued a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $60.50.

Cambrex (NYSE:CBM) opened at $53.70 on Thursday. Cambrex has a 12 month low of $42.55 and a 12 month high of $62.95. The firm has a market cap of $1,737.21, a P/E ratio of 17.90, a price-to-earnings-growth ratio of 1.28 and a beta of 2.27.

Cambrex (NYSE:CBM) last released its earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.08. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The business had revenue of $112.60 million for the quarter, compared to analyst estimates of $108.44 million. During the same period last year, the company posted $0.47 EPS. The business’s revenue was up 13.4% on a year-over-year basis.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CBM. Schwab Charles Investment Management Inc. lifted its stake in Cambrex by 3.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 150,109 shares of the biotechnology company’s stock worth $8,970,000 after purchasing an additional 4,582 shares in the last quarter. Swiss National Bank raised its position in shares of Cambrex by 2.8% during the 2nd quarter. Swiss National Bank now owns 54,400 shares of the biotechnology company’s stock valued at $3,250,000 after buying an additional 1,500 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Cambrex by 29.9% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,781 shares of the biotechnology company’s stock valued at $525,000 after buying an additional 2,020 shares during the period. Riverhead Capital Management LLC raised its position in shares of Cambrex by 90.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,264 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Cambrex by 3.4% during the 2nd quarter. Teachers Advisors LLC now owns 353,138 shares of the biotechnology company’s stock valued at $21,100,000 after buying an additional 11,592 shares during the period.

TRADEMARK VIOLATION NOTICE: “Cambrex Co. (CBM) Forecasted to Earn FY2017 Earnings of $2.96 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/18/cambrex-co-cbm-forecasted-to-earn-fy2017-earnings-of-2-96-per-share.html.

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply